Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Approved for marketing 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Oligodendroglioma 1Glioma 1Astrocytoma 1

Interventions

Temozolomide 4abemaciclib 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2vorasidenib 1pembrolizumab 1Vorinostat 1Vincristine 1Specimen Handling 1Radiotherapy, Conformal 1Protons 1Proton Therapy 1Procarbazine 1OKN 007 1Nivolumab 1Magnetic Resonance Spectroscopy 1Lomustine 1Irinotecan 1DNA Methylation 1Cyclophosphamide 1Chemotherapy, Adjuvant 1Biopsy 1BID protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Oligodendroglioma × vorasidenib × Clear all
NCT05484622 2026-03-12

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

Servier

Phase 1 Active not recruiting
60 enrolled
CNS

Astrocytoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡